LMC Login | CPMC Login | My Games Account Login
Change Region: Asia | Europe | USA | UK | RoW
Register for Updates & Free Games Account
Complete the form below to register with us for updates. We will update you when new challenges and games are available to play.
First Name:
Surname:
Country:
Email:
Re-enter email:
If you would like a free PharmaSchool Games Account so you can record your weekly GCP Challenge Scores please check the box below and add a password:
Free Games Account:
Password:
Re-enter Password:
 
 
 
Weekly GCP Challenge

Answer the questions below and then click the button. The next page will mark your answers and show you how well you have done compared with the previous people who have taken the tests.


Challenge: Ethics Committees in ICH GCP

Question Number 1:
According to ICH GCP when reviewing clinical trials IRBs/IECs should pay special attention to trials that may include what?
A
 Vulnerable subjects
B
 Placebo control
C
 Gene Therapy
D
 Medication which has no therapeutic benefit for subjects

Question Number 2:
According to ICH GCP how long should an IRB/IEC take to review a protocol and document its opinion?
A
 60 days
B
 A reasonable time
C
 90 days
D
 No longer than 6 months

Question Number 3:
According to ICH GCP what is the miminum number of members which should be present for an IRB/IEC meeting to be quorate?
A
 3
B
 4
C
 40% of members
D
 There is no specified number

Question Number 4:
According to ICH GCP which types of Adverse Events should the investigator promptly report to the IRB/IEC?
A
 All Adverse Drug Reactions
B
 All Serious Adverse Drug Reactions
C
 All Unexpected Serious Adverse Drug Reactions
D
 All Unexpected Serious Adverse Events

Question Number 5:

Which of the following does ICH GCP say the IRB/IEC should notify the investigator of in writing?

a) Its trial-related decisions/opinions

b) The reasons for its decisions/opinions

c) Procedures for appeal of its decisions/opinions
A
 a, b and c
B
 a and b only
C
 a only
D
 a and c only

Sort the Challenges
GCP & Guidelines
Trial Design
Adverse Events
Monitoring
Statistics
Abbreviations
General
Show All
International Sites: UK Europe Asia USA
PharmaSchool Ltd.
t: +44 (0) 845 224 0891 f: +44 (0) 845 224 0873 e: info@PharmaSchool.org